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Abstract
Kidney-associated pathologies would greatly benefit from noninvasive and robust methods that can
objectively quantify changes in renal function. In the past years there has been a growing incentive to
develop new applications for fluorine (19F) MRI in biomedical research to study functional changes during
disease states. 19F MRI represents an instrumental tool for the quantification of exogenous 19F substances
in vivo. One of the major benefits of 19FMRI is that fluorine in its organic form is absent in eukaryotic cells.
Therefore, the introduction of exogenous 19F signals in vivo will yield background-free images, thus
providing highly selective detection with absolute specificity in vivo. Here we introduce the concept of
19F MRI, describe existing challenges, especially those pertaining to signal sensitivity, and give an overview
of preclinical applications to illustrate the utility and applicability of this technique for measuring renal
function in animal models.
This chapter is based upon work from the COST Action PARENCHIMA, a community-driven network
funded by the European Cooperation in Science and Technology (COST) program of the European
Union, which aims to improve the reproducibility and standardization of renal MRI biomarkers. This
introduction chapter is complemented by two separate chapters describing the experimental procedure and
data analysis.
Key words Magnetic resonance imaging (MRI), Fluorine (19F), Kidney, Inflammation, Tissue
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1 Introduction
The need for methods to assess renal function that are both robust
and noninvasive is increasingly becoming recognized. One
approach is to use MRI in combination with contrast agents that
are responsive to physiological changes [1]. The most common
type of MR contrast agents are paramagnetic agents that enhance
contrast on MR images. These contrast agents act by modulating
proton (1H) relaxation, either during recovery (T1 component) or
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decay (T2 component) of the MR signal. In order for a contrast
agent to be useful to identify changes in a specific physiological
phenomenon, its sensitivity to detect and quantify physiological
changes on MRI and its pharmacokinetic properties must be
balanced [2].
From a technical point of view, paramagnetic contrast agents
have a concomitant effect on all components of MR relaxation; the
interplay between T1 and T2 relaxation depends on the dose and
location of the contrast agent as well as the MR imaging sequence
used [3]. This complexity is exacerbated by intrinsic factors such as
deoxygenated blood or air cavities that may confound the signal
being investigated [4]. A case in point is when imaging cells labeled
with contrast agent: changes in contrast created by such intrinsic
tissue factors could render the labeled cells indistinguishable from
the surrounding tissue. This drawback is heightened by the signal
sensitivity constraints due to the low concentrations of contrast
agent (<μM range). As a result, any quantification of the physio-
logical observation is hampered, and in some cases, no definitive
conclusions can be made.
The use of fluorinated agents in combination with fluorine (19F)
MRI overcomes the hurdle of signal ambiguity because the 19F MR
signal is specific to the administered 19F agent. While the 19F nucleus
has similar MR sensitivity and resonance frequency as 1H, unlike 1H,
it is practically absent in vivo, that is, there are no endogenous 19F
organic forms in vivo. Therefore, any exogenous fluorinated com-
pounds introduced in vivo can be detected with high selectivity and
absolute specificity. This has been exploited to noninvasively track
cells in vivo using 19F MRI after labeling them with 19F compounds,
typically in the form of nanoparticles (NP). Interestingly, the chemi-
cal shift range for 19F is much larger than that of 1H. Organofluorine
compounds span a chemical shift range of over 350 ppm [5]. Thus
multiple 19F nuclei resonances for organofluorine compounds can be
easily separated, even under rather inhomogeneous conditions
[6]. The unique properties of 19F nuclei as well as 19F compounds
have been the driving force behind the increasing interest in 19F
MRI. However, the application of 19F MRI to a wide range of
biomedical research fields has been restricted by the low abundance
of 19F nuclei in vivo following exogenous administration. This con-
straint is compounded by the fact that the signal sensitivity of current
MR hardware remains limited, making the detection of 19F com-
pounds present at low concentrations extremely challenging. There-
fore, one strategy in 19F MRI to circumvent this is to boost the
signal-to-noise ratio (SNR) as a function of time, that is, the SNR
efficiency to enhance signal sensitivity and improve detection limits.
From a biological perspective, several key components must be
considered when using contrast agents to study renal function.
Among other physicochemical properties, size will determine the
pharmacokinetic properties of the contrast agent as well as its uptake
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by cells in vivo. For example, low-molecular-weight-gadolinium-
based contrast agents (GBCAs) are filtered through the glomerulus
and are not reabsorbed by the renal tubule. Conversely, larger con-
trast agents such as paramagnetic iron oxide particles or 19F nano-
particles commonly follow a one-compartment pharmacokinetic
model within the blood [7]. These nanoparticles are too large to
be filtered by the glomerulus and are eventually taken up by phago-
cytic blood cells. Such nanoparticles including the iron replacement
therapy ferumoxytol have a long intravascular half-life (>14 h) and
are therefore useful for vascular and perfusion-weighted MRI
[8]. Unless inflammatory processes are ongoing, these particles will
localize primarily in the liver and will eventually undergo elimination
via hepatic clearance. The clearance of nanoparticles via liver or
kidney is dependent on their size and surface properties [9] but
also on the health status of these organs, such that clearance should
be critically studied [10] especially prior to patient studies.
This introduction chapter is complemented by two separate
chapters describing the experimental procedure and data analysis,
which are part of this book.
This chapter is part of the book Pohlmann A, Niendorf T (eds)
(2020) Preclinical MRI of the Kidney—Methods and Protocols.
Springer, New York.
2 Overview of Applications
Quantitative measurements of renal function are necessary to detect
changes already during the early stages of kidney disease, to support
disease staging and to screen emerging therapeutic strategies. Non-
invasive and rapid MR methods are needed to quantify disease
components such as inflammation, hypoxia and tissue damage.
While commonly available MR contrast agents act by modulating
1H relaxation, contrast agents containing 19F have also been devel-
oped to investigate disease components such as inflammation and to
quantify pathological changes in the tissue microenvironment (e.g.,
changes in tissue oxygenation (pO2) or pH) using
19F MRI.
2.1 19F MRI to Study
Environmental
Changes in the Kidney
In Vivo
There is an abundant repertoire of exogenous MRI contrast agents
that act by modulating 1H relaxation and which are triggered by
changes in pO2, pH or temperature as well as changes in protein,
metabolite or metal ion concentrations (reviewed elsewhere [1]).
Here we focus on the application of 19F probes that elicit a desired
MR signal following changes in pO2 and pH and hold promise as
tools for screening kidney disease.
2.1.1 Renal Tissue
Oxygenation
Healthy kidneys operate under relatively low O2 conditions, requir-
ing extensive extraction of O2 from flowing blood. While several
regulatory mechanisms act to maintain oxygenation within homeo-
static limits, the kidneys are nonetheless particularly susceptible to
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hypoxic injury [11]. While O2 consumption determines perfusion
in most nonrenal tissue such as the brain, perfusion determines O2
consumption in the kidney [12]. Therefore, a sudden temporary
impairment of the blood flow to the kidney results in acute kidney
injury (AKI) as a result of impaired O2 delivery. Approaches for
identifying and treating AKI as early as possible should aim at
detecting and restoring imbalances the homeostasis between renal
oxygenation and factors such as nitric oxide that control the renal
microcirculation [13].
Noninvasive methods to measure kidney function in vivo, spe-
cifically tissue pO2 and blood perfusion, are crucial. Arterial spin
labeling MRI determines intrarenal perfusion without the need of
exogenous contrast agents, and will be reviewed in a separate
chapter of this book. MRI techniques that utilize the native 1H
contrast from blood—blood-oxygenation-level-dependent
(BOLD) MRI—have been proposed [14]. The level of renal oxy-
genation within each voxel is quantified by mapping the shortening
of 1H T2
* induced by deoxyhemoglobin—deoxyHb [15]. How-
ever, the relation of T2
* to tissue pO2 may be confounded by factors
such as hematocrit, oxyHb dissociation curve, and the vascular
volume fraction. This underscores the need for careful scrutiny of
this relation in order to make quantitative interpretations [16].
Perfluorocarbon (PFC) emulsions offer an alternative to quan-
tify changes in tissue pO2 during vascular pathology [17, 18]. More
recently PFC NPs were also employed as a theranostic strategy for
studying perfusion and treating AKI [19]. Primarily PFC NPs have
been used to assess perfusion in the renal microvasculature follow-
ing AKI [20]. 19F MRI sensitively detected decreased RBV and
pO2 in the cortical–medullary (CM) junction 24 h following uni-
lateral (left) renal ischemia–reperfusion [20], where increased T2
*
was also observed by 1H BOLDMRI (Fig. 1a). The T2
*, 19F signal,
and pO2 in the renal cortex of injured kidneys were all comparable
to the contralateral control kidney, suggesting recovery of perfu-
sion and oxygenation in this region. In the inner medulla, however,
vascular leakage and hemorrhage-induced extravascular retention
of PFC NPs (Fig. 1b, c) resulted in a false readout of reduced 1H
T2
*, increased 19F signal intensity, and unchanged pO2.
PFCs and oxygen exhibit similarly low cohesive energy densi-
ties, such that both require little energy for mutual solubility
[21]. The high oxygen-dissolving capacity of PFC emulsions
makes them ideal as O2 carriers. PFCs were, in fact, considered as
artificial blood substitutes [22]. Fluosol-DA—a mixture of per-
fluorodecalin (PFD) and perfluorotributylamine—was the first
PFC emulsion studied in humans in a trial of Japanese patients
[23]. It was soon recalled due to its rather low oxygen transport
capacity compared to that of red blood cells [24]. PFCs ultimately
failed as blood substitutes (even as next generation products
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appeared in the clinic). Although O2-deprived tissues easily extract
O2 in PFCs, the oxygen dissociation curve of PFC emulsions is
linear and monotonic, in contrast to the sigmoidal hemoglobin
dissociation curve. Therefore, most of the O2 dissolved in PFCs is
released at high O2 partial pressure in the arteries, with little O2
being available for the capillaries where O2 partial pressure is low
but needed the most [22]. Interestingly Fluosol-DA (the first PFC
that was used in patients [23]) was also used to acquire the first 19F
MR images in vivo, showing its accumulation in the rat liver
[25]. The PFC in this emulsion gives complex MR spectra and
has since been replaced by other PFCs with better imaging
properties [26].
The longitudinal relaxation rate (1/T1) of
19F in PFCs was
shown to depend linearly on O2 partial pressure [27]. This led to
the first noninvasive in vivo tissue O2 assessments in tumor tissue
and liver [28] and later in myocardial tissue [29]. The latter study
provided the first proof of concept study for rapid, noninvasive
measurements of O2 oxygen tension changes in response to ische-
mia and reperfusion [29]. It is claimed that the size of PFC nano-
particles (>100 nm) confers upon them a good safety profile
without renal toxicity, since they are not expected to be cleared
through glomerular filtration. Therefore, unlike other imaging
agents that undergo renal clearance (e.g., iodinated CT com-
pounds, gadoliniumMRI chelates), PFC emulsions do not increase
the workload of the kidney and are not immediately considered as
nephrotoxic [10].
Fig. 1 Assessing perfusion in the renal microvasculature following acute kidney injury using PFCs. (a)
Composite Representative 1H T2*-weighted image (top row), 19F spin density weighted image (middle row),
and pO2 map (bottom row) in the left control and right injured kidneys of the same mouse. (b) Fluorescence
images showing FITC-lectin labeled perfused blood vessels in control and injured kidneys (top row) and zoom-
in view of FITC-lectin (green) labeled perfused vessels in the CM junction (bottom row). (c) Fluorescence
images showing rhodamine labeled PFC NPs in injured and control kidneys (top row) and zoom-in view
showing PFC NPs (red) in the renal medulla (bottom row). Adapted from Hu L. et al. (2013) [20] with permission
from John Wiley & Sons Inc.
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2.1.2 Acid–Base
Homeostasis in the Kidney
and pH Sensors
The kidney plays a major role in acid–base homeostasis; this balance
depends on its capacity to reabsorb filtered bicarbonate, mainly
from the proximal tubule, and to excrete an equivalent amount of
protons at the distal tubule [30]. CEST MRI was originally devel-
oped to measure pH with exogenous pH-responsive MRI contrast
agents [31]. The pH in the kidney following AKI gradually
increased from 6.7 to 7.2 as measured with CEST-MRI pH-re-
sponsive probes [32]. A major drawback of paramagnetic probes is
that signal intensity is not only proportional to the pH but also to
contrast agent concentration. Particularly in tumors, in vivo pH
mapping assumes a constant contrast agent concentration across
tissue notwithstanding poor perfusion where acidolysis
occurs [33].
Approaches such as ratiometric 19F/1H probes have been
developed to overcome the issue of quantification; the signal is
normalized to the concentration of the contrast agent by means
of a concentration reporting (19F) moiety [34]. Another advantage
of 19F MR probes is the larger range in chemical shifts in 19F
(compared to 1H). These chemical shifts are highly sensitive to
the immediate surroundings, such that small chemical changes
can lead to dramatic changes in chemical shift [6]. The first 19F
MR probe identified as a candidate to probe cellular pH was the
vitamin B6 analog 6-fluoropyridoxol (6-FPOL) reported to have a
pKa in the physiological range and large chemical shift response
[35]. Subsequently the feasibility of using 6-FPOL to probe cellular
pH was demonstrated in whole blood [36]. The concept of
employing 19F MR probes for in vivo imaging was introduced
when a series of fluorinated vitamin B6 analogs with a chemical
shift sensitivity in the range 7.4–12 ppm were synthesized as pH
indicators [37]. The sensitivity of 19F MRS probes can be further
improved by incorporating paramagnetic metal ions that further
amplify the chemical shift between protonated and deprotonated
forms by the presence of covalent and dipolar contributions
[38, 39]. Iron (II) complexes were also explored to exploit the
pH-dependent spin-state population change; the 19F NMR chemi-
cal shift was in a sensitivity range of 13.9 ppm per pH unit at 37 C
[40]. More recently fluorinated nickel (II) complexes with diamag-
netic and paramagnetic properties were designed for ratiometric
pH mapping by 19F MRI [41]. Supramolecular nanostructures
formed by fluorinated peptide amphiphiles transitioning from
cylindrical to ribbon-like shape as pH increases from 4.5 to 8.0
resulting in enhancedMR signals. These nanostructures represent a
good strategy to design stimulus-responsive 19F MRI contrast
agents for responses to pH changes in vivo [42].
2.2 19F MRI to Study
Renal Inflammation
In Vivo
Together with renal tissue hypoxia and tubular injury, inflammation
is one underlying component in the pathology of AKI [43]. Studies
suggest that systemic inflammation causes ischemic injury in one
organ and that repercussions follow in distant organs downstream
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of the ischemic event [44–46] (Fig. 2). Therefore, methods that
can non-invasively quantify the level of inflammation in different
organs would be crucial to identify the causality and significance of
inflammation during both systemic and kidney-specific disease.
19F MRI is commonly used in association with an intravenous
administration of PFC emulsions to study the distribution of
inflammatory cells in vivo [26, 47–51]. 19F MRI is performed
after an in vivo labeling of inflammatory cells with a 19F com-
pound—typically in nanoparticle (NP) form. The 19F-NPs are
administered intravenously in order for them to be taken up by
inflammatory cells that are migrating through the systemic circula-
tion into inflamed organs. Typically, PFCs such as perfluoro-15-
crown-5 ether (PFCE) are used to prepare NPs for cell labeling.
PFCE is biologically stable and provides a high payload of 19F
nuclei since it contains 20 chemically equivalent 19F spins.
In a rat model of orthotopic kidney transplantation, 19F MRI
was used to study inflammation in the kidney undergoing rejection
[48]. Three days following transplantation, PFCE NPs were admi-
nistered intravenously and 1H/19F images acquired 2 and 24 h
following NP infusion (Fig. 3a). At the earlier time point, the 19F
signal was mainly found in the circulation but also in small but
roughly equal amounts in both the native and transplanted kidneys
(Fig. 3a). By day 4 posttransplantation (i.e., 24 h following PFCE
NP), the transplanted kidney underwent moderate (Grade 2) rejec-
tion and showed an intense signal in the allograft kidney and in liver
and spleen, but the 19F signal was virtually undetectable above the
level of image noise in the native kidney (Fig. 3a). T2*-weighted
Fig. 2 Inflammation as one underlying factor in the pathology of AKI. AKI can be triggered by a variety of
clinical disorders ranging from renal ischemic events to sepsis and exposure to nephrotoxic substances. The
kidney is tightly connected with the interior milieu of the body such that even the slightest of changes will be
rapidly detected and communicated between the kidney and the rest of the body
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imaging reveals hemorrhaging in the medulla on day 4 post-kidney
transplantation, which can be detected both in animals administered
ultrasmall superparamagnetic iron oxide (USPIO) NPs but also in
transplants without USPIO (saline control) (Fig. 3b). This can
confound the detection of USPIO-labeled macrophages and exhi-
bits one of the advantages of 19F MRI over iron oxide-based NPs.
Apart from labeling inflammatory cells in vivo, NPs have been
used to label specific immune cell types such as dendritic cells (DCs)
ex vivo, prior to their administration in vivo [52–54]. This kind of
labeling is particularly useful to label cellular therapies that will be
administered in patients as part of a treatment strategy [55]. In
addition to cancer patients, kidney transplantation patients would
also benefit from cell-based therapies, specifically the types of cells
inducing tolerance [56]. Monocyte-derived suppressor cell pro-
ducts are currently being investigated alongside immunosuppres-
sive therapies in kidney transplant recipients with promising results
[57]. These candidate therapies would benefit from a labeling
strategy that will enable them to be tracked in vivo over time with
19F MRI. The possibility of quantifying the 19F MR signal would
allow an objective assessment of the spatial and temporal cellular
distribution within the same individual. This kind of labeling and
19F MRI would result in absolute cell quantification, since the 19F
MR signal is generated from the cells alone, by direct detection of
the 19F spins in the cells labeled with 19F NPs, without any con-
founding background MR signal. However, several biological and
technical considerations need to be made, in order to achieve a
truly absolute MR signal quantification: not all cell types can be
labeled with the 19F NPs currently available (Subheading 3.1.1).
Fig. 3 Inflammation in the kidney in a rat model of orthotopic kidney transplantation experiencing rejection. (a)
Composite 1H/19F images of an orthotopic kidney transplant recipient 2 h post–PCE injection on POD 3 with
19F signal found in the vasculature and equally in both the native (upper) and graft (lower) kidneys (left) and
~24 h post–PCE injection with 19F signal in the allograft kidney, as well as other organs (right). (b) Allograft
kidney on POD 4 following an injection (left) of 6 mg/kg BW USPIO (upper row) or following an injection of
saline (lower row) and 24 h later (right). Adapted from Hitchens T.K. et al. (2011) [48] with permission from
John Wiley & Sons Inc.
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3 Basic Concepts of 19F MRI
3.1 19F imaging
Probes
The design and synthesis of novel fluorine-rich molecular labels and
imaging probes is an important domain for 19F MRI. For several
years, a wide range of fluorine probes has been available for experi-
mental and even clinical applications [58, 59].
3.1.1 19F Probes
for Cellular Uptake
Current procedures used to label cells with nanoparticles take
advantage of the intrinsic nature of cells to engulf foreign bodies,
a cellular property known as phagocytosis. Dendritic cells are intrin-
sically phagocytic and therefore ideal candidates for tracking with
19F MRI [52, 53, 55, 60–62]. Cells labeled with clinical grade 19F
nanoparticles have been administered as immunotherapies in can-
cer patients [55]. This tracking method could support several other
cell therapy studies, including those dealing with kidney
transplantation [63].
Enhancing cellular uptake is desirable, even for cells that are
intrinsically phagocytic. Several studies have investigated the incor-
poration of phosphatidylserine (PS) in nanoparticle-based therapeu-
tics to enhance their uptake [64]. After renal ischemia–reperfusion,
the signal from PS-containing microbubbles was two-fold higher
than that for standard lipid microbubbles [65]. Phospholipids such
as PS and phosphatidylethanolamine (PE) are important compo-
nents of biological cell membranes and are important components
for endocytosis in phagocytic cells such as DCs [66]. We previously
reported that enrichment of 19F nanoparticles with 1,2-dipalmitoyl-
sn-glycero-3-PE (DPPE) resulted in a striking increase (at least one
order of magnitude) in cytoplasmic uptake in DCs [62]. Interest-
ingly, membrane lipid-raft processes have been proposed as traffick-
ing mechanisms for transporting therapeutic cargo such as siRNA
[67] or targeting ligands [68] into the cytoplasm, circumventing the
usual endosomal uptake pathway.
Labeling cells with low intrinsic phagocytic properties (such asT
cells) will prove more difficult using the above strategy, even if the
nanoparticle size is lower than 180 nm [69]. Some research groups
claim to have labeled T cells using the same above principles [70]. T
cells are not able to internalize nanoparticles, even small iron oxide
nanoparticles (core diameter¼ 12.5 nm), as has been clearly shown
by transmission electron microscopy (TEM), considered to be a
definitive method, and also by confocal microscopy [71]. For the
latter method nanoparticles with fluorescent tags were used to cor-
roborate the in vivo 19F signals with ex vivo fluorescencemicroscopy
signals, but the authors also included a cell membrane stain
[71].This is a necessary control todistinguishmembrane association
from intracellular distribution, in light of the point spread function
contribution [72]. Another key point is that the fluorescent tag
dissociates from the fluorine label over time, both in vitro and
in vivo [73]. This has a critical impact on the interpretation of
long-term experiments validated by standard fluorescent
techniques.
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Before taking the next steps toward administering cells in vivo,
it is essential to understand how nanoparticles are recognized,
internalized, trafficked, and distributed within the specific host
cell [74]. This is critical when contemplating labeling of cells that
may ultimately be applied in vivo to patients in a therapeutic con-
text. Cells that are not intrinsically phagocytic will not readily
internalize NPs but might still exhibit a 19F MR signal ex vivo,
due to reasons such as transitional binding of NPs to the cell
membrane or incomplete clearing of noninternalized NPs from
the cell culture medium. The 19F MR signals following administra-
tion of ineffectively labeled cells with contaminating NPs would be
misrepresentative of the actual distribution of the cells in vivo.
Therefore, we need to ask the right questions regarding the specific
cell type to be labeled, and the methods used prior to transfer of the




Fluorinated probes are commonly designed with the goal of
improving signal strength by increasing the number of fluorine
atoms per molecule [59]. Linear 19F polymers such as perfluoro-
polyethers (PFPEs) are the simplest choice to achieve increased
fluorine content but the NPs produced with these polymers are
polydisperse and the presence of multiple chemical shifts presents
several peaks in the 19F spectra [76]. Superfluorinated branched 19F
probes such as 19FIT [77] and PERFECTA [78] promise several
advantages, specifically a very high fluorine nuclei density with a
single 19F spectral peak. These probes therefore afford enhanced
sensitivity and better imaging performance than linear perfluoro-
polymers. Unlike PERFECTA [78], the bispherical fluorocarbon
19FIT is water soluble [77] and therefore possesses low organ
retention, but it cannot be emulsified into nanoparticles for cell
labeling strategies. Increasing the density of 19F nuclei can only go
so far in terms of increased sensitivity of 19F probes. Ultimately, a
limit to this density will be reached.
Another strategy to promote 19F MR signal is to manipulate
the MR properties of the 19F probes in order to favor ideal condi-
tions for MR signal acquisition. One approach is to decrease the T1
of the 19F nuclei, which is typically in the range of 0.5–3 s for
diamagnetic compounds. Paramagnetic metal ions such as lantha-
nides(III) or iron(II) reduce the T1 of
19F compounds [38]. Para-
magnetic centers affect the relaxation of 19F nuclei (paramagnetic
relaxation enhancement or PRE effect) via a number of mechan-
isms, most notably electron–nucleus dipole–dipole interaction and
Curie relaxation [39], both of which are influenced by the effective
magnetic moment (μeff) of the paramagnetic metal [79]. Other
than the μeff of the metal ion, the PRE effect is also influenced by
the distance separating the 19F nuclei and the paramagnetic metal
ion [39]. While long distances will severely diminish PRE, short
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distances will substantially shorten the spin–spin relaxation time T2.
Thus T1 reduction by molecular design should be dealt with care-
fully since it could also lead to a reduction in the T2 and thereby line
broadening of the resonance, which ultimately affects sensitivity
[80]. The most sensitive metal-based probes are, in fact, not
those whose metal ions have the highest μeff, but rather those
who have the ideal distance separating 19F from the paramagnetic
metal ion (4.5–7.5 Å) thus resulting in higher T2/T1 ratios
[81]. Nonetheless even at larger 19F–M distances (>10 Å), the
PRE effect can still be notable as is the case for a DOTA-based
19F chelator [82]. In paramagnetic PFC nanoparticles, the 19F MR
relaxation enhancement has also been explained by diffusion
mechanisms attributed to the changes in Brownian motion of
PFC molecules inside the NP in conjunction with their ability to
permeate into the lipid surfactant coating [83].
Introduction of paramagnetic metals in the design of 19F
probes not only results in a decrease T1 of
19F nuclei but also
leads to paramagnetic induced chemical shifts. The CEST signal
generated by paramagnetic involvement (PARACEST) will also be
modulated by pH (Subheading 2.1.2). A macrocyclic Fe
(II) complex bearing both exchangeable 1H and 19F was shown
to behave as a ratiometric pH-responsive MRI contrast agent,
whereby the CEST, but not the 19F MR signal was pH-dependent
[84]. This enables accurate pH mapping without the use of multi-
ple probes. More recently a DOTA macrocyclic structure com-
plexed with Ni(II) metal was shown to exhibit larger separations
between the 1H CEST signal and water [85]. Though the in vivo
application of 19F PARACEST probes remains to be investigated,
the available complexes will likely provide valuable information in





One way of improving signal sensitivity is to avoid signal losses such
as those occurring during spin relaxation. Most fluorinated com-
pounds generally have long T1 relaxation times, which effectively
increases the acquisition time. Together with the fact that there is a
large range of relaxation times for 19F MR, this motivates more
reliable optimization of pulse sequences that is informed by theMR
properties of the 19F compounds under investigation. Sequence
performance is largely dependent on the relaxation times of the
addressed spin system but also on the conditions the nuclei are in,
such as tissue oxygenation level [17].
The choice of the best pulse sequence and acquisition method
is dictated by the MR properties, particularly the relaxation times,
of the nuclei being measured. The acquisition protocol for each
sequence should be optimized by tailoring detection schemes to
the properties of the nucleus—also in relation to its environment—
using relationships empirically drawn from simulations [86]. Relax-
ation times determine the time frames of signal losses, so the time
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orchestration for data acquisition should be assigned correctly.
Other parameters, such as acquisition bandwidths, should also be
properly planned to avoid recording unnecessary noise and to
achieve the highest possible SNR [87].
A number of 19F MR studies using different pulse sequences
have aimed to optimize the acquisition method to promote SNR
efficiency and signal sensitivity [17, 87–90]. A large proportion of
19F MR studies, especially those applying perfluorocarbons (PFCs)
in vivo, have employed the turbo spin echo (SE) rapid acquisition
using relaxation enhancement (RARE) sequence [26, 47, 50, 51,
91]. This method reduces acquisition time by accumulating multi-
ple echoes (dictated by the turbo factor) within a single repetition
time [92]. Optimal settings for echo train lengths and repetition
time (TR) according to measured relaxation times (T1/T2 combi-
nations) were calculated for RARE to improve sensitivity
thresholds [90].
Although RARE is commonly been for studying PFCs in vivo,
other sequences will be better suited for 19F compounds that unlike
typical PFCs have short T2 relaxation times. In such cases signal
detection might be technically challenging and will demand acqui-
sition strategies properly adapted for the compound and its envi-
ronment. Gradient echo (GE) sequences were used to maximize
SNR efficiency for imaging paramagnetic macrocyclic 19F mole-
cules complexed to lanthanides [87]. These molecules exhibit T1
values in the order of 1–15 ms and T2* values in the order of
0.4–12 ms [88]. In the latter study a radial zero echo time (ZTE)
sequence yielded a sensitivity gain of 27-fold when compared to
nonparamagnetic molecules, while the GE sequence yielded a gain
of 11-fold [88]. Additionally, the highest SNR efficiency gain was
achieved when T2/T1were close to 1, particularly for the ZTE pulse
sequence, and when T1 was in the range of 1–5 ms [88]. Even
19F
molecules with unique spectral properties will require a more indi-
vidualized adjustment of theMR parameters; such molecules might
benefit from sequences such as ultrashort echo time (UTE) that
acquire signal before the spins dephase, taking into consideration
destructive phase interference [93]. An efficient k-space sampling
strategy will be necessary to achieve maximal SNR and artifact-free
MR images [94]. To image perfluorooctyl bromide (PFOB) that
has a rich spectrum with large chemical shifts, a radial UTE with a
balanced steady-state free precession (bSSFP) pulse sequence
showed superiority above other sequences, such as SE, GE, or
bSSFP with Cartesian sampling [89]. However, radial sampling
might not always be viable since k space sampling pattern effects
need to be considered, which might altogether result in reduced
SNR efficiency [86]. Another way to speed up data acquisition is
synchronous multinuclear imaging. For this, the MR system needs
to have the architecture suited to acquire images from more than
one nucleus in a single pulse sequence [95]. Simultaneous proton
290 Sonia Waiczies et al.
and 19F MRI was performed in a preclinical model using a clinical
MR scanner at 3 T [95].
3.3 Hardware
Considerations
The similarity between 19F and 1H MR properties with respect to
sensitivity and resonance frequency is an advantage, from an engi-
neering perspective since similar pulse power settings can be used,
and dual-tuned radio frequency (RF) coils for 19F and 1H MRI are
more convenient to design [50, 96]. One way of improving the 19F
MR signal in vivo is to increase SNR by improving the sensitivity of
the measuring instrument. Two hardware strategies to improve
sensitivity for 19F MR are to increase the strength of the static
magnetic field (B0), and to increase the sensitivity of the RF coil
by cryogenic cooling.
3.3.1 Cryogenic Cooling The sensitivity of the RF coil is an important factor limiting SNR
and thereby the level of spatial and temporal resolution that is
targeted for 19F MRI [97]. Even when employing an RF coil with
a homogeneous transmit field (B1
+) distribution and dedicated for
brain 19F and 1HMRI, the spatial resolution of in vivo 19FMRI was
limited to approximately 600 μm [50]. This level of spatial resolu-
tion prohibits a detailed understanding of inflammation dynamics.
To overcome the sensitivity constraints in 19F MR and improve
detail of inflammatory cell location, we applied the concept of
cryogenically cooling RF coil hardware to improve SNR by reduc-
ing thermal noise [98–100]. The cryogenically cooled RF coil
(CryoProbe™) technology is commercially available for small ani-
malMRI of 1H and X-nuclei such as carbon (13C) and phosphorous
(31P). For these X-nuclei this technology is expected to be particu-
larly useful for increasing SNR. A gain in SNR of 3.0- to 3.5-fold
was reported for the 13C CryoProbe [101]. We recently compared
a 19F CryoProbe with a room temperature 19F RF coil of similar
size and reported on a maximal SNR gain of 15-fold and were able
to study inflammation at an isotropic resolution of 150 μm [100].
Surface RF coils provide a very high SNR close to the region
where they are applied. However, a decrease in signal amplitude
with increasing distance from their surface is inherent to the geom-
etry of their design. Inhomogeneities in the transmit (B1
+) field
cause a spatially varying flip angle (FA) and as a result signal
quantification is hampered. Likewise, the receive (B1
) field of
surface RF coils is position-dependent [102]. In the particular
case of the 19F CryoProbe, we observed a strong FA decrease
with increasing distance from the surface of the coil [100]. Using
a receive-only surface RF coil in combination with a volume reso-
nator used for transmission would overcome B1
+ inhomogeneities.
With this configuration the transmitted FAs will be homogeneous,
thus enabling quantification [103]. This option is not available
when using CryoProbes, since they are typically built in the form
of transceive (transmit–receive) RF coils with no active decoupling.
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Particularly for quantitative 19F MRI, a correction of the B1
+ inho-
mogeneity will be necessary when comparing concentrations of
PFC in vivo with an external standard of known 19F concentration.
Differences in the B1
+ field between the region of interest in vivo
and the external standard will result in errors when quantifying
in vivo 19F signals. Several approaches have been implemented to
correct B1
+ inhomogeneities retrospectively, even for 19F MRI
[104, 105]. These approaches typically include RF pulse sequences
for which an analytical knowledge of the signal intensity depen-
dency on the FA exists.
3.3.2 Magnetic Field
Strengths
Increasing the strength of the static magnetic field (B0) will increase
SNR of the measured signal [106], a strategy which is actively being
pursued for clinical application [107]. Intrinsic SNR is expected to
grow at least linearly with increasing B0 strengths [97, 108,
109]. The principle of reciprocity can be used at low field strengths
to calculate the receive field (B1) sensitivity of a single channel RF
coil in terms of the transmit field (B1
+) that can be easily measured
[110]. In studies performed at frequency ( f ) <1 MHz the maxi-
mum sensitivity was calculated to be proportional to the f: sensitiv-
ity / f1.75 [97, 108]. When going to higher magnetic field
strengths, the increasing f and the influence of wave propagation
need to be considered [106]. The homogeneity of the B1
+ field is
expected to decline with increasing B0, thereby influencing the
overall SNR gain. An experimental study investigating SNR depen-
dency on B0 in the human brain revealed that SNR / B01.65 in the
range of 3.0–9.4 T [109]. A recent simulation study also showed
that SNR grows superlinearly with frequency, particularly in deeper
regions of the sample; in less deep regions the SNR versus B0 trend
approached linearity [111].
An increase in magnetic field strength is particularly beneficial
for X-nuclei imaging. An increase in B0 from 9.4 to 21.1 T results in
an SNR gain of ~3 compared to a gain of ~2 for 1H MR [112]. We
recently studied the influence of increasing B0 on improving
19F
MR signal sensitivity [113]. Prior to the practical experiments, we
estimated the expected SNR gain when moving from 9.4 to 21.1 T
to be 2.7 [113]. We estimated SNR gain using the principle of
reciprocity [110] and ignoring all flip angle, sequence and
relaxation-dependent effects. The estimated SNR gain represents
a baseline expectation, based on the information available for the
specific hardware of each system. When introducing the relation-
ship of the reference power for both MR systems, we estimated an
SNR gain of ~3.8. In our practical experiments the ratio in SNR
efficiency (SNR/√t ratio) was estimated to be 7.29, when compar-
ing the best possible conditions for both 21.1 and 9.4 T, and when
including T1 relaxation effects [113]. Differences between the
actual SNR gains determined experimentally and those expected
292 Sonia Waiczies et al.
from simulations are conceivable, due to minor inaccuracies in the
assumptions made for the EMF simulations.
All research efforts ranging from new 19F probe design,
through optimization of 19F MR data acquisition methods up to
hardware developments hinge on the need for promoting 19F MR
signal in vivo, in order to answer crucial questions during pathology
including kidney disease. Most of the efforts devoted to discovery
and proof-of-principle research will benefit from an integration of
all available tools and technologies, in order to reach the maximum
potential for practical applications for patient health care.
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